Delta4 is a TechBio company focused on helping clients expand indications for existing drugs with known safety profiles.
We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than traditional approaches.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque risus eros, sodales nec libero et, placerat condimentum urna. Proin ipsum elit, placerat sed porttitor at, hendrerit ac neque.
Information Needed
A drug of interest or a drug target with information on whether the target is inhibited or activated
Outcome
A ranked list of diseases with a clear biological rationale for why the drug’s mechanism of action or modulation of the drug target should have a beneficial impact on the disease.
A typical Indication Expansion engagement runs from initial kickoff through delivery of the final ranked indication report. Along the way, Delta4 keeps you updated as the Hyper-C platform narrows the disease library down to the most promising candidates.
Timelines can flex depending on the complexity of the compound or target and how many indications warrant a deeper look.
Computational drug repositioning in cardiorenal disease: opportunities, challenges and approaches
Perco P, Ley M, Kęska-Izworska K, Wojenska D, Bono E, Walter SM, Fillinger L, Kratochwill K
Proteomics 2025 25(11-12):e202400109